Literature DB >> 1896026

Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA.

H Furuya1, U A Meyer, H V Gelboin, F J Gonzalez.   

Abstract

Sequencing of genomic polymerase chain reaction (PCR) products synthesized using primers generated from the CYP2C8 and CYP2C9 cDNAs revealed the presence of a new CYP2C gene in the human genome. Primers specific to exons of this new gene were used to perform PCR on human liver cDNA libraries and cDNA synthesized from human liver mRNA to generate a cDNA containing a complete cytochrome P450 amino acid reading frame. This cytochrome P450 cDNA, designated CYP2C18, displayed 85% and 87% nucleotide and 77% and 81% amino acid sequence similarities, respectively, with cDNAs and proteins corresponding to CYP2C8 and CYP2C9. cDNA-directed synthesis of CYP2C18 revealed a protein with relative Mr 49,000 on sodium dodecyl sulfate-polyacrylamide gels, which is considerably less than that calculated from the deduced amino acid composition, Mr 55,747. A preferred substrate for this enzyme has not been uncovered. Levels of CYP2C8, CYP2C9, and CYP2C18 mRNAs were examined in 17 human liver specimens using a PCR-based assay. CYP2C18 mRNA was found in all livers examined, albeit at mean levels 7-8-fold lower than those of mRNAs encoding CYP2C8 and CYP2C9. Marked interindividual differences in levels of expression of all three CYP2C mRNAs were also found.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1896026

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

Review 1.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

2.  N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity.

Authors:  H J Gill; M D Tingle; B K Park
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

Review 3.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.

Authors:  K Brøsen; E Skjelbo; H Flachs
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

5.  In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.

Authors:  D J Birkett; D Rees; T Andersson; F J Gonzalez; J O Miners; M E Veronese
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

6.  Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.

Authors:  David J Elliot; Benjamin C Lewis; Elizabeth M J Gillam; Donald J Birkett; Annette S Gross; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2007-05-22       Impact factor: 4.335

Review 7.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Authors:  J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

8.  Human cytochromes P450: evolution and cDNA-directed expression.

Authors:  F J Gonzalez; H V Gelboin
Journal:  Environ Health Perspect       Date:  1992-11       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.